Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study.

Zappitelli M, Washburn KK, Arikan AA, Loftis L, Ma Q, Devarajan P, Parikh CR, Goldstein SL. · 2007

Read Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. by Zappitelli M, Washburn KK, Arikan AA, Loftis L, Ma Q, Devarajan P, Parikh CR, Goldstein SL. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2206519.txt.

Introduction

Zappitelli and co-workers tested a urine marker in 2007 to spot acute kidney injury early in critically ill children. The standard marker, serum creatinine, rises late after damage. The candidate protein, called NGAL, rises early when injury timing is known. Whether it predicts injury in general intensive care was unclear. The team followed 140 ventilated children, collecting urine daily and grading kidney injury by paediatric criteria.

Urine NGAL rose at least six-fold in children developing kidney injury. The rise came two days before and after the creatinine jump, while controls stayed flat. NGAL predicted new injury with an accuracy measure of 0.78, and persistent injury lasting 48 hours or more with 0.79 on the same measure. It rose step by step with worse final injury grade. That supports its use as an early warning test in this setting.

Catalog record

CREATORZappitelli M, Washburn KK, Arikan AA, Loftis L, Ma Q, Devarajan P, Parikh CR, Goldstein SL.
YEAR2007
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2206519

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study By Michael Zappitelli, Kimberly K Washburn, Ayse A Arikan, Laura Loftis, Qing Ma, Prasad Devarajan, Chirag R Parikh, Stuart L Goldstein Published in: Critical Care DOI: 10.1186/cc6089 ABSTRACT Introduction Serum creatinine is a late marker of acute kidney injury (AKI). Urine neutrophil gelatinase-associated lipocalin (uNGAL) is an early marker of AKI, where the timing of kidney injury is known. It is unknown whether uNGAL predicts AKI in the general critical care setting. We assessed the ability of uNGAL to predict AKI development and severity in critically ill children. Methods This was a prospective cohort study of critically ill children. Children aged between 1 month and 21 years who were mechanically ventilated and had a bladder catheter inserted were eligible. Patients with end-stage renal disease or who had just undergone kidney transplantation were excluded. Patients were enrolled within 24 to 48 hours of initiation of mechanical ventilation. Clinical data and serum creatinine were collected daily for up to 14 days from enrollment, and urine was collected once daily for up to 4 days for uNGAL measurement. AKI was graded using pRIFLE (pediatric modified Risk, Injury, Failure, Loss, End Stage Kidney Disease) criteria. Day 0 was defined as the day on which the AKI initially occurred, and pRIFLEmax was defined as the worst pRIFLE AKI grade recorded during the study period. The χ2 test was used to compare associations between categorical variables. Mann-Whitney and Kruskal-Wallis tests were used to compare continuous variables between groups. Diagnostic characteristics were evaluated by calculating sensitivity and specificity, and constructing receiver operating characteristic curves. Results A total of 140 patients (54% boys, mean ± standard deviation Pediatric Risk of Mortality II score 15.0 ± 8.0, 23% sepsis) were included. Mean and peak uNGAL concentrations increased with worsening pRIFLEmax status (P < 0.05). uNGAL concentrations rose (at least sixfold higher than in controls) in AKI, 2 days before and after a 50% or greater rise in serum creatinine, without change in control uNGAL. The parameter uNGAL was a good diagnostic marker for AKI development (area under the receiver operating characteristic curve [AUC] 0.78, 95% confidence interval [CI] 0.62 to 0.95) and persistent AKI for 48 hours or longer (AUC 0.79, 95% CI 0.61 to 0.98), but not for AKI severity, when it was recorded after a rise in serum creatinine had occurred (AUC 0.63, 95% CI 0.44 to 0.82). Conclusion We found uNGAL to be a useful early AKI marker that predicted development of severe AKI in a heterogeneous group of patients with unknown timing of kidney injury. INTRODUCTION Severe acute kidney injury (AKI) increases morbidity and mortality of hospitalized patients [1-3]. Recent evidence suggests that a small reduction in renal function, indicated by serum creatinine (SCr), is an independent predictor of mortality and length of hospital stay [1,4]. Laboratory research has revealed that early intervention may be essential in preventing the pathophysiologic events that lead to AKI [5,6]. Unfortunately, SCr – the main AKI biomarker used in the clinical setting – is a late marker of reduced glomerular filtration rate, which limits ability to detect AKI early and to initiate clinical therapeutic studies. Therefore, recent research has focused on identifying earlier biomarkers of AKI [7-12]. Neutrophil gelatinase-associated lipocalin (NGAL), a ubiquitous 25 kDa protein, was isolated as a potential biomarker of AKI using genomic microarray technology [12,13]. NGAL is generally expressed in low concentrations, but it increases greatly in the presence of epithelial injury and inflammation [12,14,15]. Mishra and coworkers [16] observed a significant rise in uNGAL (uNGAL) 2 days before the rise in SCr in children with AKI following cardiopulmonary bypass (CPB). These findings have now been confirmed in a prospective study of adults who developed AKI after cardiac surgery [17], which found uNGAL to be significantly elevated by one to three hours after the operation. Other human studies [18-20] demonstrated a strong relationship between uNGAL and AKI in renal transplantation, diarrhea-associated hemolytic-uremic syndrome, and lupus nephritis. It is unknown whether the association between uNGAL and AKI can be generalized to the critical care setting, in which the population is heterogeneous and AKI etiology and timing are often unclear. Furthermore, the prevalence of sepsis in the intensive care unit (ICU) may limit the use of uNGAL as a specific biomarker of kidney injury. We studied uNGAL concentrations in a group of critically ill children with the following goals: to determine whether there is an association between uNGAL and AKI in this heterogeneous group; to evaluate the effect of sepsis and illness severity on the use of uNGAL to predict AKI; to determine the extent to which uNGAL concentrations increase before SCr in the setting of an unknown timing of initial kidney injury; and to evaluate the sensitivity and specificity of uNGAL to predict the clinical course of AKI. MATERIALS AND METHODS Study design and subject selection This study was performed concurrently with a prospective observational study that validated pRIFLE (pediatric modified Risk, Injury, Failure, Loss, End Stage Kidney Disease) criteria for defining AKI in critically ill children [21]. Patients aged 1 month to 21 years, admitted to the pediatric ICU (PICU), who received mechanical ventilation and underwent indwelling bladder catheterization, were eligible for enrollment. Patients with end-stage renal disease and who had just undergone renal transplantation were excluded. Patient care givers provided written informed consent for the child to participate in the descriptive study of AKI and for collection of urine samples. The study protocol and consent forms were approved by the Baylor College of Medicine Human Subjects Institutional Review Board before study initiation. Clinical data collection The following clinical variables were evaluated: patient age, sex, height, and weight; admission and discharge diagnoses; vasopressor use (yes/no) and number of vasopressors used; renal replacement therapy provision; and 28-day mortality. Patients with an admission or discharge diagnoses of sepsis, septic shock, or systemic inflammatory response syndrome were classified as having sepsis. The Pediatric Risk of Mortality (PRISM) II score (a measure of severity of illness/mortality risk) was calculated on the day of ICU admission [22]. Laboratory data collection SCr values were obtained prospectively as part of routine patient care from the day of enrollment up to 14 days of the study (or until PICU discharge if this occurred before 14 days). At study completion, SCr values from PICU admission to study enrollment were recorded retrospectively. Estimated creatinine clearance (eCCl) was calculated using the Schwartz formula [23]. Patients were classified daily by pRIFLE criteria for AKI, using changes in eCCl from baseline eCCl (Table 1). Each patient's first AKI occurrence using pRIFLE criteria and the worst pRIFLE status (pRIFLEmax) attained over 14 days were recorded. Baseline renal function was defined as the lowest known SCr value during the preceding 3 months. Patients without known prior SCr were assumed to have normal baseline renal function and assigned a baseline eCCl of 120 ml/min per 1.73 m2. This cutoff was chosen because the Schwartz eCCl overestimates glomerular filtration rate. For those patients with no known baseline SCr and a PICU admission eCCl greater than 120 ml/min per 1.73 m2, their PICU admission eCCl was recorded as their baseline renal function. [Table:

Read the complete text